Intercure Ltd. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Intercure performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Intercure is an Israeli medical cannabis company that manages the entire process, from growing plants to selling products in their own "Cannol" pharmacies. Their business has two main parts:

• Cannabis: This is their primary revenue source. They grow, process, and sell medical cannabis flowers, oils, and vaporizers.
• Biomed: This division focuses on developing medical technology and pharmaceuticals, leveraging their existing facilities and regulatory experience.

2. How they measure success

Because Intercure is in a growth phase, they focus on "Adjusted EBITDA." This metric serves as a proxy for day-to-day operational profit by excluding one-time costs, non-cash expenses like stock-based compensation, and costs specifically related to the October 7 attacks. This approach is intended to show how the core business performs without the immediate impact of regional conflict.

3. Financial Health: The Cash Flow Update

The most significant development this year is the company’s cash flow. After facing challenges in 2023 and 2024 due to regional conflict, Intercure reported positive cash flow from operations for 2025.

While this is a major milestone, management notes that consistent profitability in 2026 depends on successfully expanding their pharmacy network and production capacity without further setbacks. The company raised approximately $18.2 million in 2025 through the sale of additional shares. Management has indicated that they may seek further funding through loans or additional share issuances, which would dilute the percentage of ownership held by existing shareholders.

4. Major Wins and Challenges

• The "War" Factor: Their Southern Facility in Kibbutz Nir Oz is their most significant operational risk. Because it is located in a conflict zone, regional instability poses a direct threat to production, staff safety, and physical assets.
• Third-Party Reliance: Intercure relies on outside suppliers and distributors. Any failure by these partners to adhere to strict quality or legal standards could result in product recalls or supply chain disruptions.
• The "Import Tax" Battle: Israel is considering a 175% tax on cannabis imported from Canada. If implemented, this would significantly increase costs, potentially making these products too expensive for the local market.

5. Key Risks for Investors

• Reporting Rules: As a foreign company, Intercure is not required to follow all U.S. SEC rules. They do not file quarterly reports and have fewer requirements regarding executive pay and board independence compared to domestic U.S. companies.
• Data Privacy: The company handles sensitive patient data. A data breach or failure to comply with strict privacy laws could lead to heavy fines and long-term damage to their reputation.
• Operational Strain: International expansion is complex. The company faces risks related to fluctuating currency values, varying tax laws, and the logistical challenge of managing operations across different countries.
• Market Volatility: As a smaller, growth-focused company, Intercure’s stock price is sensitive to news regarding the conflict in Israel and shifts in global cannabis regulations, which can lead to significant price swings.

Final Thoughts for Your Decision: When considering an investment in Intercure, weigh the company's recent achievement of positive cash flow against the significant geopolitical risks inherent in their primary production location. Because they are a smaller, growth-stage company operating in a volatile region and a heavily regulated industry, they are best suited for investors who are comfortable with higher levels of risk and uncertainty.